1.59
0.02 (1.27%)
Previous Close | 1.57 |
Open | 1.58 |
Volume | 22,749 |
Avg. Volume (3M) | 59,372 |
Market Cap | 59,453,440 |
Price / Sales | 0.850 |
Price / Book | 1.54 |
52 Weeks Range | |
Earnings Date | 27 Aug 2025 |
Profit Margin | -34.33% |
Operating Margin (TTM) | -44.22% |
Diluted EPS (TTM) | -0.680 |
Quarterly Revenue Growth (YOY) | -9.10% |
Total Debt/Equity (MRQ) | 36.23% |
Current Ratio (MRQ) | 1.74 |
Operating Cash Flow (TTM) | -14.91 M |
Levered Free Cash Flow (TTM) | -10.11 M |
Return on Assets (TTM) | -16.54% |
Return on Equity (TTM) | -49.28% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Distribution (US) | Mixed | Bearish |
Medical Distribution (Global) | Mixed | Bearish | |
Stock | EDAP TMS S.A. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | -1.00 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others. |
|
Sector | Healthcare |
Industry | Medical Distribution |
Investment Style | Small Value |
% Held by Institutions | 41.38% |
Ownership
Name | Date | Shares Held |
---|---|---|
Bruce & Co., Inc. | 31 Mar 2025 | 553,652 |
Cahill Financial Advisors Inc | 31 Mar 2025 | 134,960 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
01 Jul 2025 | Announcement | EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status |
15 May 2025 | Announcement | EDAP Reports First Quarter 2025 Financial Results |
01 May 2025 | Announcement | EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025 |
29 Apr 2025 | Announcement | EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting |
24 Apr 2025 | Announcement | EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting |
22 Apr 2025 | Announcement | EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |